At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Sumanta K. Pal, MD, of City of Hope Comprehensive Cancer Center, Duarte, CA, discusses the results of the international phase 2 Borealis-1™ trial, which evaluated the efficacy and safety of gemcitabine and cisplatin plus apatorsen, a novel antisense oligonucleotide that inhibits Hsp27 production, in patients with advanced bladder cancer.
Borealis-1™: Phase 2 trial of gemcitabine/cisplatin plus apatorsen in advanced bladder cancer
13th August 2015
Join our mailing list
To receive the EMJ updates straight to your inbox free of charge, please click the button below.Join Now